Brokerages predict that Omeros Co. (NASDAQ:OMER) will report ($0.12) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have provided estimates for Omeros’ earnings, with estimates ranging from ($0.22) to ($0.02). Omeros reported earnings of ($0.53) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 77.4%. The business is expected to report its next quarterly earnings report on Thursday, May 9th.
According to Zacks, analysts expect that Omeros will report full year earnings of ($0.31) per share for the current fiscal year, with EPS estimates ranging from ($0.78) to $0.17. For the next fiscal year, analysts anticipate that the business will post earnings of $0.81 per share, with EPS estimates ranging from ($0.96) to $2.57. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that cover Omeros.
Omeros (NASDAQ:OMER) last released its earnings results on Friday, March 1st. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.75) by $0.37. The company had revenue of $22.02 million for the quarter, compared to analyst estimates of $22.42 million. Omeros’s revenue for the quarter was up 60.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.34) earnings per share.
Several institutional investors have recently made changes to their positions in OMER. JPMorgan Chase & Co. increased its position in shares of Omeros by 65.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 15,421 shares of the biopharmaceutical company’s stock worth $376,000 after purchasing an additional 6,116 shares in the last quarter. BlackRock Inc. increased its position in shares of Omeros by 1.0% during the 3rd quarter. BlackRock Inc. now owns 3,957,936 shares of the biopharmaceutical company’s stock worth $96,614,000 after purchasing an additional 38,349 shares in the last quarter. Allianz Asset Management GmbH increased its position in shares of Omeros by 15.1% during the 3rd quarter. Allianz Asset Management GmbH now owns 73,815 shares of the biopharmaceutical company’s stock worth $1,802,000 after purchasing an additional 9,694 shares in the last quarter. Tocqueville Asset Management L.P. increased its position in shares of Omeros by 24.7% during the 3rd quarter. Tocqueville Asset Management L.P. now owns 23,700 shares of the biopharmaceutical company’s stock worth $579,000 after purchasing an additional 4,700 shares in the last quarter. Finally, Man Group plc acquired a new stake in shares of Omeros during the 3rd quarter worth about $286,000. Institutional investors and hedge funds own 49.28% of the company’s stock.
NASDAQ:OMER traded up $0.23 during trading hours on Thursday, hitting $18.69. 7,533 shares of the company traded hands, compared to its average volume of 477,474. The stock has a market cap of $902.53 million, a P/E ratio of -8.39 and a beta of 3.60. Omeros has a twelve month low of $10.30 and a twelve month high of $27.00.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
See Also: What is a Roth IRA?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.